Blincyto, illustration of injection vial form (not a photo of the actual pack)

Illustrative image.

Blincyto

Blinatumomab

Prescription required

$4980.00

38.5MCG · 35

BrandBranded medicine· By Amgen

Choose a pack

  • Selected pack

Packs in this delivery

1

Test mode: no payment is taken. View cart

Ships cold, in insulated packing

This medicine ships in insulated packing with coolant and carries its own shipping charge, shown at checkout.

Prescription required

Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.

FDA boxed warningCytokine release syndrome and neurological toxicities including immune effector cell-associated neurotoxicity syndrome

Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO. Interrupt or discontinue BLINCYTO and treat with corticosteroids as recommended.

Neurological toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS) which may be severe, life-threatening, or fatal, occurred in patients receiving BLINCYTO. Interrupt or discontinue BLINCYTO as recommended.

Read this with the rest of the clinical information

About Blincyto

Overview

Blincyto contains blinatumomab and treats CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children aged one month and older. It is used in first or second complete remission when minimal residual disease (MRD), leukemia cells remaining after treatment, is at least 0.1%, or when the leukemia has returned or has not responded to treatment. It is also used during the consolidation phase of multiphase chemotherapy for CD19-positive, Philadelphia chromosome-negative B-cell precursor ALL. It works by linking immune cells called T cells to cells carrying CD19, helping the T cells destroy those cells.

What it treats

For adults and children aged one month and older with: • CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission, with minimal residual disease (MRD) of at least 0.1%. • CD19-positive B-cell precursor ALL that has returned or has not responded to treatment. • CD19-positive, Philadelphia chromosome-negative B-cell precursor ALL during the consolidation phase of multiphase chemotherapy.

Safety information

Side effects

Common side effects of Blincyto include fever, infusion-related reactions, headache, infections, muscle and bone pain, nausea, diarrhea, and low levels of white blood cells called neutrophils, red blood cells (anemia), or platelets. Serious side effects that warrant contacting a doctor include cytokine release syndrome, neurological problems including immune effector cell-associated neurotoxicity syndrome, infections, tumor lysis syndrome, low neutrophil counts with or without fever, elevated liver enzymes, inflammation of the pancreas (pancreatitis), and damage to the brain’s white matter (leukoencephalopathy). Do not drive or operate heavy or potentially dangerous machinery while Blincyto is being administered. Blincyto may harm an unborn baby; those who could become pregnant should use effective contraception.

FDA boxed warning

Cytokine release syndrome and neurological toxicities including immune effector cell-associated neurotoxicity syndrome

Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO. Interrupt or discontinue BLINCYTO and treat with corticosteroids as recommended.

Neurological toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS) which may be severe, life-threatening, or fatal, occurred in patients receiving BLINCYTO. Interrupt or discontinue BLINCYTO as recommended.

A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.

When to call your doctor

- Seek medical attention immediately for fever or signs of infection. - Seek medical attention immediately for a severe headache.

If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.

Before taking this medicine

Do not use Blincyto if you have a known allergy to blinatumomab or any other ingredient in the product. Blincyto requires monitoring for signs and symptoms of infection. Symptoms suggesting pancreatitis need medical assessment; treatment may need to be paused or stopped. Blincyto may harm an unborn baby. Females who could become pregnant should use effective contraception. For newborns, Blincyto must be prepared with preservative-free saline. Blincyto solution containing benzyl alcohol is not recommended for patients weighing less than 5.4 kg. Do not drive, operate heavy or potentially dangerous machinery, or perform hazardous activities while Blincyto is being administered. Preparation and administration instructions must be followed strictly to avoid errors.

Interactions

No formal drug interaction studies have been conducted with Blincyto. When treatment starts, a temporary release of cytokines may reduce the activity of CYP450 enzymes, which help break down certain medicines. Tell your doctor if you take warfarin, cyclosporine or other medicines processed by these enzymes, especially those where small changes in blood levels can cause harm. The interaction risk is highest during the first 9 days of the first treatment cycle and the first 2 days of the second cycle. Your doctor may monitor for toxicity or check medicine levels in your blood and adjust the other medicine if needed.

Using Blincyto

Dosing

Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.

Storage

Store in the original carton below 25°C, protected from light, unless the pack states refrigeration. Do not freeze. Keep all medicines out of the sight and reach of children.

Clinical information on this page is summarised from the US FDA label BLINCYTO (BLINATUMOMAB) KIT [AMGEN, INC] (DailyMed, retrieved 19 September 2026).

Reviews

No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.

  • Every prescription order is checked by a licensed pharmacist before dispensing.
  • Payment pages are encrypted and card details never reach our servers.
  • We ship internationally, with cold-chain packing where a medicine needs it.

Related medicines